TickerSparkInvestor Intelligence
TickerSparkInvestor Intelligence
Custom Reports
Stock Deep Dives · Free to Try
AI Analyst
Agentic Chat · Free to Try
Watchlist
Track Your Stocks · Free
Spark Charts
AI Technical Analysis · Free to Try
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio · Pro
My Portfolio
Brokerage Connected · Pro
Custom Reports
Stock Deep Dives
AI Analyst
Agentic Chat
Watchlist
Your Stocks & Notes
Spark Charts
AI Technical Analysis
Trade Tracker
AI-Managed Portfolio
My Portfolio
Brokerage Connected
Main Feed
Today's Market Intel
Stock Reports
AI Research Reports
Top Stocks
AI-Curated Stock Lists
Commentary
Opinionated Stock Takes
Stock Teasers
The Stock Behind the Promo
Trending Stocks
Today's Big Movers
Earnings Coverage
Flashes & Deep Dives
Macro Updates
Economy & Markets
IPO Calendar
Upcoming Listings
CommunityDashboard
Log inCreate Account
← Back to TickerSpark
▌Earnings Flash·August 4, 2026

Gilead Sciences, Inc. (GILD) gains on earnings beats

Gilead Sciences, Inc. (GILD) gains 2.6% after reporting earnings beats, as investors react positively to stronger-than-expected results and improved outlook.

Earnings FlashGILDHealthcareDrug Manufacturers - General
By TickerSpark·August 4, 2026·2 min read
Gilead Sciences, Inc. (GILD) gains on earnings beats
▌Key Takeaway
Gilead Sciences (GILD) posted a double beat, with EPS of -$6.75 versus -$7.26 expected and revenue of $7.80B versus $7.40B expected. Shares rose 2.55% after hours to $134.50, signaling investors rewarded the stronger-than-expected sales and smaller-than-expected loss, even though EPS remained negative.

Gilead Sciences, Inc. (GILD) Earnings Beat, Stock Gains

Gilead Sciences, Inc. (GILD) delivered a double beat, posting EPS of -$6.75 versus -$7.26 expected and revenue of $7.80B versus $7.40B, while shares gained 2.55% in after-hours trading to $134.50.

Key Numbers

  • EPS: -$6.75 actual versus -$7.26 expected, a beat.

§ Product

  • How It Works
  • Custom Reports
  • AI Analyst
  • Intel Dashboard
  • Spark Charts
  • Trade Tracker
  • My Portfolio
  • Plans

§ Research

  • Main Feed
  • Community
  • Stock Reports
  • Macro Updates
  • Blog

§ Company

  • About Us
  • Contact

§ Fine Print

  • Terms of Service
  • Privacy Policy
  • Full Disclaimer
  • Cookie Policy

Notice: All content and data on TickerSpark is for informational purposes only and does not constitute financial or investment advice. All investments involve risk. Please see our Full Disclaimer for more details.

© 2026 Maxwell Cyberlogic LLC

Not Investment Advice

Made in Delaware, USA

Revenue: $7.80B actual versus $7.40B expected, a beat.
  • After-hours reaction: $134.50, up 2.55% from the $131.15 regular-session close.
  • Trading activity: 10,078,462 shares versus a 7,613,759 average.
  • EPS trend: Actual EPS exceeded estimates in all five quarters listed.

    • A Revenue Beat, With EPS Still in Focus

    GILD's double beat gives investors a strong near-term signal. Reported revenue exceeded the estimate, and EPS was less negative than expected. The caveat is equally concrete: EPS remained below zero at -$6.75. Top-line strength alone does not settle the earnings question.

    The after-hours response adds a positive market verdict. Shares rose from $131.15 to $134.50, while trading volume topped the listed average. The move shows that traders rewarded the combination of stronger revenue and a smaller-than-expected EPS loss.

    The recent record reinforces the result. The five quarters listed in GILD's earnings history all show actual EPS above estimates, including four positive-EPS beats before this quarter. The earnings call's most important detail is the bridge from $7.80B of revenue to -$6.75 EPS, which will shape the view of earnings quality.

    Get AI research on any stock

    Instant reports, daily intelligence, and an AI analyst in your pocket.

    Get Started →

    Bottom Line

    GILD delivered a double beat and earned a 2.55% after-hours gain, but the negative EPS result keeps earnings quality at the center of the investment case.

    Read the full GILD research report
    ▌Common Questions

    Frequently asked questions

    +Did Gilead Sciences beat earnings this quarter?
    Yes. Gilead Sciences (GILD) reported EPS of -$6.75 versus -$7.26 expected and revenue of $7.80B versus $7.40B expected, a double beat. The stock rose 2.55% in after-hours trading to $134.50.
    +Why did GILD stock go up after earnings?
    GILD gained because investors reacted positively to both a revenue beat and an EPS result that was less negative than expected. The shares moved from the regular-session close of $131.15 to $134.50 after hours on heavier-than-average trading.
    +What were Gilead Sciences' earnings and revenue versus estimates?
    Gilead Sciences reported EPS of -$6.75, compared with the -$7.26 estimate. Revenue came in at $7.80 billion versus the $7.40 billion consensus estimate.
    +What does Gilead's latest earnings report mean for investors?
    The report is a near-term positive because GILD beat on both revenue and EPS, and the stock responded favorably after hours. However, EPS was still negative, so investors will continue to focus on whether the company can convert stronger sales into better earnings quality.
    ▌The Daily Briefing · Free

    A new stock idea, every evening.

    One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.

    Daily market recap + weekly preview. One-click unsubscribe in every email.

    ▌The Full Report

    Want the full picture on GILD?

    The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.

    Read the GILD report →Get Full Access →

    Not ready to subscribe? ·

    ▌The Full Report

    Get the full GILD research report

    • Analyst-grade deep dive
    • Charts, valuation, grades
    • Buy/sell price targets
    Read the GILD report →
    ▌For Active Investors

    Smarter research, on every ticker

    • Daily market intelligence
    • On-demand stock analysis
    • AI analyst chat
    Get Full Access →

    Cancel anytime

    ▌The Daily Briefing · Free

    A new stock idea, every evening.

    One stock worth watching each weekday, free in your inbox.

    Daily market recap + weekly preview. One-click unsubscribe in every email.

    ▌More on GILD

    More to read

    All articles
    Gilead Sciences (GILD): HIV Momentum Drives a Buy Case
    GILD

    Gilead Sciences (GILD): HIV Momentum Drives a Buy Case

    Gilead’s HIV franchise is accelerating, with Yeztugo, Trodelvy, and a stronger pipeline offsetting pressure in Veklury and cell therapy. The stock looks attractive for moderate-risk investors with a medium-term horizon.

    Aug 4·18 min
    IDEXX Laboratories, Inc. (IDXX) gains on deep earnings analysis
    IDXX

    IDEXX Laboratories, Inc. (IDXX) gains on deep earnings analysis

    IDEXX Laboratories, Inc. (IDXX) gains after a Q2 beat, but the real story is in the details: recurring diagnostics growth, margin expansion, and a raised 2026 outlook. This deep-dive breaks down segment performance, pricing, instrument trends, and what the guidance implies for the stock.

    Aug 4·7 min
    Sanofi (SNY): Dupixent Growth Supports a Hold
    SNY

    Sanofi (SNY): Dupixent Growth Supports a Hold

    Sanofi combines strong Dupixent momentum, improving margins, and solid cash generation with a more leveraged balance sheet and a valuation that looks fair rather than cheap. The result is a patient Hold case for medium-term investors.

    Aug 3·21 min